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Abstract
Mutational changes coupled with endocrine, paracrine, and/or autocrine signals regulate cell division during carcino-
genesis. The hormone signals remain undefined, although the absolute requirement in vitro for fetal serum indi-
cates the necessity for a fetal serum factor(s) in cell proliferation. Using prostatic cancer cell (PCC) lines as a
model of cancer cell proliferation, we have identified the fetal serum component activin A and its signaling through
the activin receptor type II (ActRII), as necessary, although not sufficient, for PCC proliferation. Activin A induced
Smad2 phosphorylation and PCC proliferation, but only in the presence of fetal bovine serum (FBS). Conversely,
activin A antibodies and inhibin A suppressed FBS-induced PCC proliferation confirming activin A as one of multiple
serum components required for PCC proliferation. Basic fibroblast growth factor was subsequently shown to syner-
gize activin A–induced PCC proliferation. Inhibition of ActRII signaling using a blocking antibody or antisense-P de-
creased mature ActRII expression, Smad2 phosphorylation, and the apparent viability of PCCs and neuroblastoma
cells grown in FBS. Suppression of ActRII signaling in PCC and neuroblastoma cells did not induce apoptosis as
indicated by the ratio of active/inactive caspase 3 but did correlate with increased cell detachment and ADAM-15
expression, a disintegrin whose expression is strongly correlated with prostatic metastasis. These findings indicate
that ActRII signaling is required for PCC and neuroblastoma cell viability, with ActRII mediating cell fate via the regu-
lation of cell adhesion. That ActRII signaling governs both cell viability and cell adhesion has important implications
for developing therapeutic strategies to regulate cancer growth and metastasis.
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Introduction
Mutations in tissue stem cells coupled with epigenetic changes pro-
mote carcinogenesis. However, despite the fact that these “hard-
wiring” changes are necessary for neoplasia, the cancer phenotype
is environment-dependent, as illustrated by the fact that cancer cells
can revert to a normal phenotype when injected into certain tissues.
For example, hepatocyte carcinoma cells injected into the liver inte-
grate into hepatic plates and differentiate into hepatocyte-like cells
that are morphologically and functionally indistinguishable from ma-
ture hepatocytes, whereas those injected subcutaneously lead to death
[1–3]. Likewise, injection of aggressive melanoma cells into zebrafish
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embryos [4–6] or epithelial cancer cells into mammary gland stroma
[7] leads to normalization. These results indicate that “hardwiring”,
although necessary for carcinogenesis, is insufficient for driving can-
cer growth and that signals from the immediate microenvironment
regulate cell division.
Despite a vast amount of data indicating that various factors regulate
cancer cell division, the exact tissue derived and circulating mitogenic
and/or differentiation signals remain undefined, due in part to the ease
of using fetal bovine serum (FBS) for in vitro cell growth. To address
this question, we have focused our investigations on prostatic cancer
cell (PCC) lines because PCC alter their responsiveness to hormones
throughout the course of the disease. Early-stage prostate cancer is
routinely treated with androgen-deprivation therapies, including the
suppression of androgen production with gonadotropin-releasing hor-
mone (GnRH) agonists and/or by peripheral blockage with nonsteroi-
dal antiandrogens [8–10]. However, despite initial tumor regression,
hormone-independent cells frequently emerge from such treatments
and with a more aggressive phenotype [8,11,12]. These cells seem to
undergo a transformation whereby there are alterations in androgen re-
ceptor signaling [13–17] and they developmetastatic properties [12]. Al-
though these cells may be androgen-insensitive, they continue to divide
in vivo, and when cultured in vitro, they only divide in the presence of
serum, suggestive of neoplastic responsiveness to multiple mitogens.
Aside from sex steroid receptors, receptors for other hypothalamic-
pituitary-gonadal (HPG) hormones have been reported in this re-
productive tissue and associated cell lines, including GnRH receptor
[18–20], luteinizing hormone (LH) receptor (Vadakkadath Meethal
et al., unpublished data), follicle-stimulating hormone (FSH) receptor
[21], and activin receptors [22–25]. Interpretation of the data gener-
ated from in vitro studies analyzing the effects of these hormones on
PCC lines cultured in fetal serum [21,23,26–28] has been compli-
cated by the complexity introduced by multiple serum factors (present
in FBS). Because the incidence of prostate cancer is correlated with
changes in these serum reproductive hormones [29], we examined
the responsiveness of PCC to signaling through these known mitogen
receptors using low serum conditions and strategies to antagonize
(rather than stimulate) receptor signaling. Our results indicate that
activin receptor type II (ActRII) signaling dictates PCC fate; sufficient
ActRII signaling is permissive of proliferation whereas suppression of
ActRII signaling leads to the up-regulation of ADAM-15 expression
and cell detachment. Similar results were found for a neuroblastoma
cell line. The centrality of ActRII-mediated ADAM-15 expression as
a modulator of cancer cell adhesion and viability has obvious thera-
peutic implications.
Materials and Methods
Antibodies and Reagents
The antihuman ActRIIB affinity-purified mouse monoclonal anti-
body (A0856) was purchased from US Biological (Swampscott,
MA) and recognizes the plasma membrane domain of the recep-
tor. It does not cross-react with ActRIIA. The mouse antihuman
activin recognizes human activin (US Biological). The antihuman
phosphorylated-Smad2 affinity-purified rabbit polyclonal antibody
(40-0800) recognizes Smad2 when it is dually phosphorylated at
Ser465 and Ser467 (Zymed Laboratories, South San Francisco, CA).
Antihuman ADAM-15 rabbit affinity-purified polyclonal antibody
(Chemicon International, Millipore, Billerica, MA) recognizes the
C-terminus amino acid sequence RPAPPPPAASSLYL. Antihuman
caspase 3 (E-8) mouse monoclonal antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA). The glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) goat polyclonal antibody (V-18), the anti-
human β-actin goat polyclonal antibody (C-11), and the horseradish
peroxidase–linked goat antimouse, goat antirabbit, and donkey anti-
goat IgG were purchased from Santa Cruz Biotechnology.
Recombinant human activin A (βA, βA) peptide was purchased
from R&D Systems (catalog no. 338-AC; Minneapolis, MN). Human
pituitary FSH (hFSH) and human pituitary LH (hLH) were purchased
from the National Hormone and Peptide Program, Harbor-UCLA
Medical Center (Torrance, CA). Human chorionic gonadotropin was
purchased from RayBiotech (Norcross, GA). GnRH1 peptide was pur-
chased from Bachem California, Inc (Torrance, CA). Epidermal growth
factor (EGF) and insulin-like growth factor 1 (IGF-1) were purchased
from Sigma-Aldrich (St. Louis, MO). Basic fibroblast growth factor
(bFGF) was purchased from Invitrogen (Carlsbad, CA). Low-weight
prestained (∼20 to 110 kDa) molecular weight markers were from
Bio-Rad Laboratories (Hercules, CA).
ActRII Antisense Oligonucleotides
For experiments using oligomers with phosphorothioate bonds
(antisense-P; Integrated DNA Technology, Coralville, IA), oligomers
were added to the medium (240 μl) that had been preincubated with
lipofectamine (4 ng/μl; Invitrogen) for 5 minutes at room temperature.
This mixture was then incubated at room temperature for 20 minutes
before adding to the cells. Antisense-P was used at a final concentration
of 0.4 μM. ActRIIA: antisense-P, 5′-TCCAGTTCAGAGTCCCATT
TC-3′, 21nt, 49% G/C; sense, 5′-GAAATGGGACTCTGAACTG-
GA-3. ActRIIB: antisense-P, 5′-TCTCCCGTTCACTCTGCCAC-3′,
20nt, 60% G/C; sense, 5′-GTGGCAGAGTGAACGGGAGA-3′.
Cell Culture
PC-3 and LNCaP cells were graciously provided by Dr. Wade
Bushman (University of Wisconsin, Madison, WI). PC-3 cells are
androgen-insensitive cells derived from a grade 4 human prostate
adenocarcinoma of epithelial origin [30,31]. Cells were maintained
at 37°C in F-12 Nutrient Mixture (Ham; Gibco, Invitrogen) supple-
mented with 1% penicillin-streptomycin (P/S; Gibco, Invitrogen),
2 mM glutamine (Invitrogen), 0.4 mM sodium bicarbonate (Sigma),
and 5% FBS (no. 26400-036; Gibco, Invitrogen). LNCaP cells are
androgen-sensitive human prostate adenocarcinoma cells derived from
a supraclavicular lymph node metastasis [32,33]. LNCaP cells were
maintained at 37°C in RPMI 1640 medium (Cellgro, Manassas,
VA) supplemented with 1% P/S, 2 mM glutamine, 18 mM sodium
bicarbonate, 10 mM HEPES (Invitrogen), 1 mM sodium pyruvate
(Invitrogen), 25 mM glucose (Sigma), and 10% FBS. Human M17
neuroblastoma cells were obtained from Dr. Robert Petersen (Case
Western Reserve University, Cleveland, OH) and maintained at 37°C
in OPTI-MEM medium (Invitrogen) containing 0.5% FBS and
1% P/S as previously described [34]. Fetal bovine serum concentrations
used in each experiment are listed in the figure legends. For the MTS
proliferation assay, cells were cultured in sterile 96-well plates (Falcon,
Franklin Lakes, NJ); for cytology, cell number, and immunoblot analy-
ses, cells were plated in sterile six-well plates (Nunc, Rochester, NY).
Determination of Cell Number
Cells were plated at serum levels (typically 1%) and confluence
levels (typically 40%) that allowed unrestricted growth throughout the
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time (typically 1-3 days) of the experiment under our serum conditions.
Cell number was assessed using the trypan blue (Invitrogen) staining
technique in experiments where there were few treatment conditions.
In experiments containing multiple (i.e., serum and/or hormone) treat-
ments, cell proliferation was assayed using the CellTiter 96 AQueous
Non-Radioactive Cell Proliferation Assay (MTS tetrazolium assay;
Promega, Madison, WI) as described. Briefly, cells were incubated with
MTS/PMS solution, and the absorbance was read immediately (back-
ground control) and then again after 3 hours (final reading) at 490 nm
using a 96-well plate reader (Spectramax Plus384; Molecular Devices
Corporation, Sunnyvale, CA). Background absorbance values were sub-
tracted from the final reading, and values were presented as a percentage
of the absorbance value of the control group.
Cytology
The treated PC-3 cells were examined using a Zeiss Axiovert in-
verted microscope connected to a Fluo Arc light source, and images
were captured with an Axio CamMRC-5 camera using Axio Vision 4.0
software (Zeiss Axiophot, Thornwood, NY).
Immunoblot Analysis
Cells grown in six-well plates were collected in 80 μl of lysis buffer
(20 mM Tris, 150 mM NaCl, 1% SDS, 1 mM EDTA, and 1 mM
EGTA, pH 7.6) containing protease inhibitors (10 μg/ml aprotinin
and leupeptin, 1 μg/ml pepstatin A, 1 mM phenylmethanesulfonyl
fluoride; Roche Diagnostics, Basel, Switzerland). Cells were directly
sonicated using an ultrasonic processor continuously at a frequency
of 20 Hz for 45 seconds followed by 1.5 minutes of cooling on ice.
Three cycles were performed per sample. Protein was then determined
using the bicinchoninic acid assay (Pierce, Rockford, IL), and equal
amounts of protein were loaded onto 10% to 20% tricine gels (Novex,
San Diego, CA). Samples were transferred onto polyvinylidine fluoride
membranes (Bio-Rad Laboratories), fixed with 4% glutaraldehyde in
Tris-buffered saline (TBS; 20 mM Tris, 150 mM NaCl, pH 7.6) con-
taining Tween-20 (TBST), blocked with 10% milk in TBST for
2 hours, and incubated with primary antibody in 5% milk in TBST
overnight at 4°C. On the second day, the primary antibody was re-
moved, and the blot was washed in TBST and incubated with the ap-
propriate secondary antibody for 2 hours at room temperature, washed
again in TBST, and developed with Western Blotting Luminol Re-
agent (Santa Cruz Biotechnology) or ECL Plus (Amersham, Little
Chalfont, England). The chemiluminescent signal was captured on film
(Eastman Kodak Company, Aurora, IL). Additional immunoblot anal-
yses were performed after the removal of antibodies from the blot using
Restore stripping buffer (Pierce). Captured images were scanned, and
the intensity of the autoradiograph signals (including a blank region)
was determined using the NIH Image J software. Control and treat-
ment values were corrected for blank values and normalized to their
respective GAPDH or β-actin band intensity; the results were then ex-
pressed as either a fold or percentage change over control levels.
Statistical Analyses
Statistical analysis was performed using one-way and multivariate
analysis of variance followed by pairwise comparisons with Fisher’s
protected least significant difference procedure to determine significant
changes between treatment groups (Statview 5.0 and SuperAnova 3.0
programs; SAS Institute, Inc, Cary, NC).
Results
Activin A Is Required for PCC Proliferation
To examine potential mitogens of hormone-refractory PCCs, we
treated androgen-insensitive PC-3 cells (a model of hormone-refractory
prostate cancer) with FBS. As expected, increasing concentrations of
FBS significantly increased PC-3 cell proliferation, whereas treat-
ment of cells with heat-inactivated FBS (at 100°C for 5 minutes) sup-
pressed PC-3 cell proliferation (Figure 1A). These results suggest that
a serum protein factor(s) is required for the proliferation of androgen-
insensitive PCCs.
Because PC-3 cells are androgen-insensitive [31] and serum tes-
tosterone levels decline with aging (reviewed in [35]), we sought to
examine other growth factors as mitogenic candidates for androgen-
independent cells. Consequent to the decline in serum testosterone
levels with aging and the loss of negative feedback on the hypothala-
mus and pituitary, there is a dramatic change in the synthesis, secre-
tion, and serum concentrations of all HPG hormones [36]. Therefore,
given that prostate cancer is an age-dependent disease, we tested
whether other HPG hormones are mitogenic to androgen-insensitive
PCCs. Of the hormones tested (LH, human chorionic gonadotropin,
FSH, GnRH, activin A), only activin A at physiological concentrations
(0.5-2.5 μg/L) [37] induced a significant increase in PC-3 cell pro-
liferation in the presence of 1% serum after 24 hours (Figure 1B).
At 1% serum, all hormone receptors of the HPG axis are highly ex-
pressed (Vadakkadath Meethal et al., unpublished results). No HPG
hormones induced PCC proliferation in the absence of serum. Block-
ing activin A signaling with physiological concentrations of the antag-
onist inhibin A (60,000 mIU/ml) suppressed serum-induced PC-3 cell
proliferation by 50% confirming that activin A present in serum in-
duces PC-3 cell proliferation. Similarly, treatment of PC-3 cells with
an activin A–specific antibody suppressed serum-induced PC-3 prolifera-
tion in a dose-dependent fashion by 20% and 31% with 20- and
50-μg/ml antibodies, respectively, compared with control (n = 4, P <
.01). Together, these results suggest that activin A present in FBS
[37] is permissive of PC-3 cell proliferation but that multiple different
activins or other mitogenic ligands present in serum also promote pro-
liferation independently or in synergism with activin A.
Activins signal through two classes of serine/threonine kinases,
namely, type I (a.k.a. ALK) and type II (ActRII), and mediate their
signals through a family of downstream transcription factors known
as Smads that, on phosphorylation by the activin receptor complex,
induce gene transcription [38–41]. To confirm that activin A was sig-
naling through activin receptors previously reported on normal and
transformed PCCs [22–25], we treated PC-3 cells with activin A
and measured the phosphorylation of the transcription factor Smad2.
Immunoblot analysis demonstrated a dose- and time-dependent in-
crease in activin A–induced Smad2 phosphorylation (45 kDa) such
that by 3 days of treatment, P-Smad2 expression (normalized to
GAPDH expression) was increased 81% with 2.5 ng/ml activin A,
compared with that of control (Figure 1C). Taken together, these re-
sults implicate activin A–induced receptor activation and MH2 do-
main phosphorylation [39,42–44] in activin A signaling in PC-3 cells.
To confirm that activin signaling is essential for androgen-insensitive
PCC proliferation, we inhibited activin A signaling through its
cognate receptor using a blocking antibody specific to the plasma
membrane domain of both ActRIIA and ActRIIB. This antibody
not only blocked further cell growth but also significantly decreased
PC-3 cell viability by 64% compared with the day 0 control (Figure 2A).
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Addition of activin A (2.5 ng/ml) to ActRII antibody-treated PC-3
cells did not significantly increase PC-3 cell proliferation (40 ±
11% activin A + ActRII antibody treated vs 24 ± 3% ActRII antibody
treated only; mean ± SEM, n = 4, NS). Because blocking ActRII sig-
naling reduced cell viability well below day 0 control levels, these re-
sults suggest that ActRII signaling is a basic cell requirement.
To confirm that the ActRII blocking antibody was inhibiting
activin A signaling, we probed immunoblots of the cells treated for
3 days in Figure 2A with antibodies to ActRII and P-Smad2. Nor-
malization of ActRII signals against GAPDH indicated that the
ActRII blocking antibody markedly decreased the expression of the
70-kDa form of ActRII (90%) compared with day 3 control (Fig-
ure 2B). The decline in the expression of the 70-kDa form of ActRII
was marked by an increase in the expression of a 45-kDa variant of
ActRII, indicating that suppression of ActRII signaling promotes the
proteolytic processing of the 70-kDa variant (the 45-kDa band is un-
likely to represent residual added ActRII antibody or cross-reactivity
because it was absent in the control). This suggests a negative feedback
mechanism of Smad signaling on ActRII expression and that any de-
cline in signaling through the ActRII/Smad2/Smad4 pathway might
induce ActRII proteolysis (and internalization?) and decrease cell via-
bility. The ActRII blocking antibody also decreased P-Smad2 signal
(normalized to GAPDH) by 67% compared with the day 3 control
(Figure 2C). These changes in the expression of ActRII and P-Smad2
reaffirm the specificity of the blocking antibody for ActRII signaling.
Together, these results indicate that activin A signaling through ActRII
is a basal requirement for normal PCC viability and proliferation.
Activin has previously been shown to suppress androgen-sensitive PCC
proliferation [23]. Under low serum conditions (1%), activin A did
not markedly alter the proliferation of androgen-sensitive PCCs cells
(LNCaP; data not shown). We next blocked ActRII signaling in
LNCaP cells expecting that this would either not affect cell viability
or increase cell proliferation. Surprisingly, blocking ActRII signaling
with the ActRII blocking antibody blocked LNCaP cell growth as
well as decreased cell viability, as was observed for the PC-3 cells
(Figure 2A). After 3 days of treatment with blocking antibody, LNCaP
cell number had decreased by 92%.
Blocking ActRII Signaling Induces ADAM-15 Expression
and Morphologic Changes in PCC
Suppression of ActRII signaling with the blocking antibody in-
duced significant morphological changes in PC-3 cells; cells became
rounded with fewer processes, had a smaller appearance (Figure 2D),
and readily detached from the plate. Decreasing ActRII signaling
with double-stranded (ds) antisense oligonucleotides to ActRIIA,
ActRIIB, and Smad2 induced similar morphological changes in
PC-3 cells (Figure W1 and Table 1). Blocking ActRII signaling with
the blocking antibody also induced similar morphological changes
in LNCaP cells (Figure 2E , right panels). To examine whether sup-
pression of activin signaling induces cell detachment through an
Figure 1. Serum-dependent activin A–induced proliferation and signaling in PCCs. (A) PC-3 cells plated at 50% confluence for 24 hours
in F12 medium without serum were then treated with medium containing increasing concentrations (0, 1%, 5%, and 10%) of FBS (S)
or heat-inactivated FBS (HI). Proliferation was assessed using the MTS assay after 24 hours of treatment. Results are representative
of three repetitions and presented as mean ± SEM; n = 8 (S) or 4 (HI) (*significantly different from 0% serum, P < .0001; #significantly
different from serum treated cells, P < .05). (B) PC-3 cells were plated at 40% confluence in serum free or 1% FBS medium for 24 hours
before being treated with and without activin A. Cells were treated with physiologically relevant concentrations of serum hormone as
indicated on the figure and in [98]. Cell proliferation was assessed using the MTS assay after 3 days. Results are presented as mean ±
SEM and are representative of five separate experiments (*significantly different from 0 and 1% serum alone, n = 4, P < .05). (C) PC-3
cells were plated at 50% confluence in medium containing 1% serum for 24 hours before being treated with activin A (0.5 or 2.5 ng/ml)
in 1% FBS. Whole-cell lysates collected at 1 hour and 3 days after treatment were subjected to immunoblot analysis using a rabbit anti-
human P-Smad2 antibody and goat antihuman GAPDH antibody was used as the loading control.
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apoptotic mechanism, we measured the expression of the inactive
(32 kDa) and active (17 to 22 kDa) forms of caspase 3 in cells treated
with the ActRII blocking antibody or antisense-P to ActRIIA or
ActRIIB (Figure 2F). Suppression of ActRII signaling with antisense-P
did not alter the ratio of active/inactive caspase 3, whereas the ActRII
antibody induced a 40% decrease in active/inactive caspase 3 expres-
sion. These results indicate that suppression of ActRII signaling does
not induce apoptosis.
Figure 2. Blocking antibody suppression of ActRII signaling inhibits PCC adhesion and viability. PC-3 or LNCaP cells were plated in 10%
serum at 40% confluence for 24 hours, after which cells were either collected (day 0 control) or treated every day for 3 days with 1)
medium containing 5% serum or with 2) medium containing 5% serum plus ActRII monoclonal antibody (25 μg/ml), before collection.
(A) PC-3 (upper panel) and LNCaP (lower panel) cell viability was measured using the trypan blue staining assay. Results are presented as
a percentage change from the untreated day 3 control (mean ± SEM; n = 4, P < .01; different letters indicate significant differences
between treatments; experiments were repeated five times). (B) Immunoblot analysis of PC-3 cells using a mouse monoclonal antibody
against human ActRII (70 kDa) and normalization against GAPDH (37 kDa). (C) Immunoblot analysis of PC-3 cells using an affinity purified
rabbit polyclonal antibody against human phosphorylated Smad2 (45 kDa) and normalization against GAPDH (37 kDa). (D) PC-3 cells
were cultured in F12 medium with 5% serum for 1 day before treatment ± antihuman ActRII antibody (20 μg/ml) for 3 days. Morphology
was then assessed using a Zeiss Axiophot inverted microscope. Magnification is given on the figure. Scale, 50 μm. (E) PC-3 cells (left
panels) were cultured in F12 medium with 5% serum, and LNCaP cells (right panels) were cultured in RPMI-1640 medium with 5%
serum for 1 day before treatment ± antihuman ActRII antibody (20 μg/ml) for 3 days. Original magnification, ×100. Scale, 400 μm.
(F) Immunoblot analysis of PC-3 cells described in Figure 3 for caspase 3 (32-kDa inactive and 17- to 22-kDa active forms) using a mouse
monoclonal antibody. (G) Immunoblot analysis of PC-3 cells described in (A) for ADAM-15 (70 kDa) using a rabbit antihuman ADAM-15
antibody and normalization against β-actin (47 kDa) using a goat antihuman β-actin antibody. Experiments were repeated two times.
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Together with our previous findings that blocking ActRII signal-
ing decreases PC-3 and LNCaP viability (Figure 2A) and increases
cell detachment, our results suggested that ActRII signaling may modu-
late the attachment of cells through extracellular matrix (ECM) proteins
to surrounding cells and to the surface of the plate. This increased cell
detachment may be attributed to increased ECM protein degradation
as a result of the increase in the expression/activity of ECM-degrading
enzymes such as matrix metalloproteinases. In this context, it has re-
cently been demonstrated that the expression of ADAM-15 disintegrin,
which cleaves integrin molecules (see [45] for a recent review), is
strongly correlated with the metastatic potential of prostate, breast
[46], and pancreatic cancers [47]. Furthermore, ADAM-15 has been
shown to be involved in cell migration and invasion [48,49]. To test
the hypothesis that activin A signaling mediates the adhesion of cells
through the regulation of ECM proteins, PC-3 cells were incubated
with the ActRII blocking antibody and the expression of ADAM-15
was measured. Suppression of ActRII signaling with the blocking
antibody for 3 days increased the expression of ADAM-15 3.4-fold
(Figure 2G). ADAM-15 expression after treatment with ActRII block-
ing antibody was time-dependent, increasing 14-fold after 24 hours
and declining to ∼2- to 3-fold after 3 days (data not shown). These
results suggest that blocking ActRII signaling decreases the prolifera-
tive potential of PC-3 cells by decreasing cell adhesion.
To further confirm these results, we used antisense-P to suppress
ActRIIA and ActRIIB signaling. Like the blocking antibody (Fig-
ure 2A), antisense-P to ActRIIA and ActRIIB decreased cell viability
by 43% and 73% compared with sense controls, respectively (Fig-
ure 3A). Antisense-P to both ActRIIA and ActRIIB potently sup-
pressed the expression of ActRII in PC-3 cells by 73% and 96%,
respectively (Figure 3B). This suppression of ActRIIA and ActRIIB
expression correlated with 1.5- and 2.1-fold increases in ADAM-15
expression, respectively, above the respective sense controls (Figure 3C).
These results are consistent with that observed using the blocking
antibody (Figure 2) and together indicate that blocking ActRII signal-
ing increases ADAM-15 expression and cell detachment and therefore
decreases cell viability.
ActRII Signaling Regulates Neuroblastoma Cell Viability
and Proliferation
To determine whether activin signaling was a general requirement
for the viability and proliferation of other cancer cell lines, we treated
a neuroblastoma cell line (M17) with increasing concentrations of
the ActRII blocking antibody. The ActRII blocking antibody in-
duced a dose-dependent decrease in cell viability (Figure 4A). Similarly,
antisense-P to ActRIIB (but not ActRIIA) induced a significant 43%
decrease in cell viability compared with sense control (Figure 4B),
indicating that ActRIIB signaling in neuroblastoma cells, like prostate
cancer cells, is necessary for cell viability. Like PC-3 and LNCaP cells,
treatment of M17 neuroblastoma cells with anti-ActRII blocking anti-
body induced rounded cells with fewer processes, a generally smaller
appearance, and increased detachment from the plate (Figure 4C ). Sup-
pression of ActRIIB expression with antisense-P increased ADAM-15
expression four-fold (Figure 4D), suggesting that ActRIIB signaling
also regulates cell attachment in neuroblastoma cells. These results
indicate that ActRIIB signaling may be universally important for regu-
lating cell viability and proliferation.
Synergistic Effect of Hormones on PCC Proliferation
Our results indicate that ActRII signaling is an absolute requirement
for cell proliferation but that it is not sufficient because activin A,
in the absence of serum, does not significantly increase PCC pro-
liferation (Figures 1 and 5). Because fibroblast growth factors (FGFs)
are expressed at increased levels in prostate cancer [50–52] and given
that bFGF (FGF2) is required along with transforming growth fac-
tor β (TGF-β)/activin signaling for the growth of human embryonic
stem cells [53], we determined the effect of bFGF with and with-
out activin A in the presence and absence of serum. Interestingly, like
activin A, bFGF, either in the presence or in the absence of serum,
did not increase PCC proliferation (Figure 5). However, bFGF cul-
tured in the presence of 1% serum plus activin A increased prolifera-
tion 30%, compared with control (1% serum plus activin A).
Because there also is an increased localization of IGF [54–56] and
EGF [57–60] in the prostate tumor epithelium, we next tested these
growth factors for PCC proliferation with and without activin A in
the absence and presence of serum. Epidermal growth factor and IGF-1
did not induce PC-3 cell proliferation in the presence or absence
of 1% serum and/or activin A (Figure 5). There was a trend for a
decrease in cell proliferation with IGF-1, which returned to control
levels with addition of activin A (Figure 5). These results suggest
that bFGF can synergize with activin A to induce cell proliferation,
but only in the presence of serum, indicating that other serum fac-
tors contribute to PCC proliferation. Together, these results indicate
that multiple (at least two) mitogenic/differentiation signals are required
for PCC proliferation.
Discussion
Multiple Cell Signaling Factors Are Required for
PCC Proliferation
That cancer cells require FBS for growth in vitro and that circulat-
ing serum factors are required for cancer cell growth in vivo are well
recognized. From our experiments using antisense and antibody-
blocking strategies, we have identified activin signaling through ActRII
as an absolute requirement for serum induced PCC and neuroblas-
toma cell proliferation (Figures 1–5). These data support previous find-
ings indicating that whereas mutational changes to apoptotic genes are
required for the growth of tumors, this alone is insufficient to promote
cancer cell proliferation [1–7]. Although activin A was found to be nec-
essary, it was not sufficient, to stimulate prostatic and neuroblastoma
cell proliferation in vitro (Figures 1–5), suggesting that at least two serum
Table 1. Oligonucleotide Sequences Used for Gene Silencing.
Gene Sequence No. Oligonucleotides G/C Content
ActRIIA
Antisense 1 5′-GCCAACTTTGCAGCAGCGTCCA-3′ 22nt, 59%
2 5′-AGCTCCCATTTTCCCGAGGCG-3′ 21nt, 62%
3 5′-GGCAAACGCCAACTTTGCAGCAG-3′ 23nt, 56%
Sense 1 5′-TGGACGCTGCTGCAAAGTTGGC-3′
2 5′-CGCCTCGGGAAAATGGGAGCT-3′
3 5′-CTGCTGCAAAGTTGGCGTTTGCC-3′
ActRIIB
Antisense 1 5′-GCCACCCAGGCGCCGTCATG-3′ 21nt, 76%
2 5′-AGAGGAGGGCGAGGGCCA-3′ 18nt, 72%
3 5′-AGGGCCACCCAGGGCGCCGTCA-3′ 22nt, 77%
Sense 1 5′-CATGACGGCGCCTGGGTGGC-3′
2 5′-TGGCCCTCGCCCTCCTCT-3′
3 5′-TGACGGCGCCCTGGGTGGCCCT-3′
370 Activin Signaling and Cancer Cell Adhesion Simon et al. Neoplasia Vol. 11, No. 4, 2009
factors are required for in vitro cancer cell proliferation. Indeed, the
only other system examined to date assessing the hormonal require-
ments for cell proliferation in vitro has found that, under defined culture
conditions, both a bFGF and a TGF-β family member are necessary
for the proliferation of pluripotent human embryonic stem cells [53].
However, whereas bFGF synergized with activin A to enhance PCC
proliferation, neither hormone alone nor in combination induced
PCC proliferation in the absence of serum (Figure 5). Importantly, these
results indicate that PCC, like human embryonic stem cells, also re-
quires more than one mitogenic factor to proliferate. Other than activin
A and bFGF, the specific serum components required to promote PCC
proliferation in defined conditions remain to be identified. Given our
findings, it is important that any in vitro cell culture experiment per-
formed using serum take into account the synergistic effect of the added
hormonal factor(s) with serum factors.
ActRII Signaling Is Obligatory for Serum-Induced PCC
and Neuroblastoma Cell Proliferation
The absolute requirement for ActRII signaling for normal PCC via-
bility and proliferation was indicated by 1) activin A–induced Smad2
phosphorylation and proliferation of PCC; 2) inhibition of FBS-induced
PCC proliferation by both a specific activin A antibody and inhibin A; 3)
suppression of FBS-mediated PCC viability, concurrent with the dra-
matic decrease in both Smad2 phosphorylation and ActRII expression,
by an ActRII blocking antibody; 4) inhibition of activin A–induced
PC-3 cell growth in the presence of ActRII blocking antibody; 5) inhibi-
tion of PCC proliferation in the presence of ActRII antisense-P oligo-
nucleotides; and 6) the increase in ADAM-15 expression, alteration
in cell morphology, and increase in cell detachment with suppressed
ActRII signaling (Figures 1–5). Suppression of ActRII signaling in-
duced similar morphological changes for both LNCaP and PC-3 cells,
Figure 3. Antisense oligonucleotide suppression of ActRII signaling inhibits PCC adhesion and viability. PC-3 cells were plated in 10%
serum at 40% confluence for 24 hours, after which cells were either collected (day 0 control) or treated every day for 3 days with 1)
medium containing 10% serum plus lipofectamine (control), plus 2) sense-P oligonucleotide to ActRIIA (sense A), 3) antisense-P oligo-
nucleotide to ActRIIA (antisense A), 4) sense-P oligonucleotide to ActRIIB (sense B), or 5) antisense-P oligonucleotides to ActRIIB (anti-
sense B; final concentration of 0.4 μM each). (A) PC-3 cell viability was measured using the trypan blue staining assay. Results are
presented as number of cells (mean ± SEM; n = 3-6; (*significantly different from day 3 control, P < .005). (B) Immunoblot analysis
of ActRII (70 kDa) was performed using a mouse monoclonal antibody against human ActRII and normalization against β-actin (47 kDa)
using a goat antihuman β-actin antibody. Quantitation of blot is shown on the right. (C) Immunoblot analysis of PC-3 cells for ADAM-15
(70 kDa) using a rabbit antihuman ADAM-15 antibody and normalization against β-actin (47 kDa) using a goat antihuman β-actin antibody.
Quantitation of blot is shown on the right.
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suggesting a critical role for ActRII signaling independent of androgen
receptor signaling. Similar biochemical, morphological, and viability data
indicated that M17 neuroblastoma cell adhesion, viability, and prolifera-
tion also were modulated by ActRII signaling (Figure 4).
A growing body of data suggests potential roles of activin and inhibin,
members of the TGF-β superfamily of growth hormones, as local
regulators of normal and abnormal prostate gland growth [61,62].
Evidence supporting the role of these proteins in the regulation of
prostatic epithelial cell (PEC) proliferation includes the different ex-
pression and localization of inhibin α and β subunits by normal,
malignant, and benign prostatic cells. Importantly, the βA subunit
and dimeric activin (βA, βA) have been shown to be expressed by
normal [63,64], malignant [28], benign [25], and prostate cancer
cell lines [27], whereas inhibin α has been shown to be expressed
by normal differentiated epithelial cells only [63,65] in benign pros-
tate hyperplasia and in nonmalignant regions of prostate carcinoma
[66] but is not detected in malignant prostatic cells or prostate can-
cer cell lines [66,67]. Whether activin A–induced PCC proliferation
is normal or abnormal may depend on the expression of inhibin be-
cause inhibin serves to antagonize the action of activin [22] by com-
peting for binding to ActRII, consequently, blocking activin action
[68,69]. Indeed, addition of inhibin A to FBS reduced PC-3 cell num-
ber. A role for inhibin in tumor suppression is indicated from studies
of inhibin-deficient mice where both male and female animals develop
gonadal tumors [70]. The loss of inhibin expression has been correlated
with numerous cancers (see [61] for review). For example, a loss of ex-
pression of the inhibin α subunit is associated with high-grade prostate
[66] and breast cancer [71], and as mentioned above, inhibin is not
Figure 4. ActRII signaling regulates cell proliferation, viability, morphology, and attachment of M17 neuroblastoma cells. (A) Human M17
neuroblastoma cells cultured in OPTI-MEM medium were plated in 0.5% FBS at 40% confluence. After 24 hours, wells were treated
with the antihuman ActRII mouse monoclonal antibody (0, 10, or 20 μg/ml). Cell proliferation was assessed using the MTS assay after
3 days. Results are presented as percentage change from the control (mean ± SEM; n= 3; *significantly different from control, P< .001).
Ab = antibody. (B) M17 cells were plated in 10% serum at 40% confluence for 24 hours, after which cells were either collected (day 0
control) or treated every day for 3 days with 1) medium containing 10% serum plus lipofectamine (control), plus 2) sense-P oligonucleotide
to ActRIIA (sense A), 3) antisense-P oligonucleotide to ActRIIA (antisense A), 4) sense-P oligonucleotide to ActRIIB (sense B), or 5) anti-
sense-P oligonucleotides to ActRIIB (antisense B; final concentration of 0.4 μM each). M17 cell viability was measured using the trypan
blue staining assay. Results are presented as number of cells (mean ± SEM; n = 4; *significantly different from day 3 control, P < .005).
(C) M17 neuroblastoma cells cultured in OPTI-MEM medium were plated in 0.5% FBS for 1 day before treatment ± antihuman ActRII
antibody (20 μg/ml) for 3 days. Original magnification, ×100. Scale, 400 μm. (D) M17 cells were plated exactly as in Figure 4B, and im-
munoblot analysis was performed for ADAM-15 as in Figure 3C. Quantitation of blot is shown on the right.
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detected in malignant prostatic cells or prostate cancer cell lines [66].
Thus, the age-related increase in activin A signaling with the loss of
inhibin expression with the dysregulation of the HPG axis [36] may
well explain the prostatic neoplasia observed with aging. In support
of this, activin A serum concentrations are significantly increased in
both prostate and breast cancer patients compared with sex-matched
controls; within prostate patients, those with bone metastasis had
higher serum activin A compared with those without [29].
Given this in vivo data, it is therefore puzzling why activin has
been shown to actually inhibit the proliferation of primary cultured
prostate cells [72] and androgen-sensitive prostate cancer cell lines
[22,73,74] in a dose- and time-dependent manner. One explanation
is that these studies used relatively high FBS concentrations (∼10%).
We have demonstrated that under such conditions, the expression of
ActRII and the downstream Smad2 signaling cascade is significantly
downregulated in PC-3 cells (Vadakkadath Meethal et al., unpub-
lished data). Thus, activin A signaling may be suppressed, or alterna-
tively, addition of exogenous activin A may further downregulate
ActRII expression and signaling such as is seen with GnRHR agonists
[75], thereby limiting cell proliferation. This is supported by the inhi-
bition of PCC proliferation observed with the ActRII blocking anti-
body and antisense treatments (Figures 2 and 3).
About androgen-insensitive PCCs, previous studies using exogenous
activin A failed to demonstrate any change in PC-3 cell proliferation
[23,73], whereas in our experiments, activin A induced proliferation
of PC-3 cells when used at physiological concentrations (∼1-2 μg/L;
Figure 1B) [37]. The lack of activin-induced PC-3 cell prolifera-
tion in previous studies may be due to the higher FBS (and therefore
activin A) concentrations used, thereby masking the effect of exoge-
nous activin A [23]. Along these lines, high concentrations of serum
may promote considerable expression of the activin ligand follistatin
[27], thereby blocking activin signaling. Alternatively, as discussed
above, the increased concentration of inhibin α subunit in high con-
centrations of FBS may antagonize activin A [22,68,69], thereby in-
hibiting activin-induced PC-3 cell proliferation.
ActRII signaling was found to be essential for the proliferation of
both androgen-sensitive LNCaP cells and androgen-insensitive PC-3
cells (Figure 2); receptors for ActRIIB are expressed in both cell types
[23,74]. Previous studies have shown that activin A and follistatin
proteins are expressed and secreted by PC-3 cells, but although LNCaP
cells express activin A, they do not seem to secrete it [27,73]. These
findings indicate a gain of function by androgen-insensitive and meta-
static cells in the production of a growth/detachment factor crucial for
cell proliferation/mobilization. Similarly, because activin A is necessary
for LNCaP cell proliferation, the results suggest paracrine production
of activin A within the prostate [63,64,73] for normal PEC growth.
That only activin A, but not other HPG hormones, induce a prolifera-
tive response in the presence of serum is consistent with the fact that
the suppression of serum LH, FSH, and testosterone concentrations
with GnRH superagonists eventually becomes ineffective at suppressing
tumor growth [8,76].
Considerable evidence exists that activin signaling plays a role in can-
cer. Activin A has been found to be overexpressed in stage IV colorectal
cancer [77], whereas activin A mRNA levels correlate with poor prog-
nosis for esophageal carcinoma [78]. Activins are known to stimulate
cell growth in ovarian cells [22] and are elevated in the serum of women
with ovarian tumors [79]. High levels of activin postoperatively strongly
correlate with recurrence of ovarian cancer [79]. Elevated serum activin
also has been reported in endometrial tumors, and levels decline after
surgical removal of the tumor [80].
Basic Fibroblast Growth Factor Synergizes with Activin A
to Enhance PCC Proliferation
Growth of PCC is dependent on interactions with the prostate
stroma and ECM through integrin and growth factor receptor–
mediated systems [81–86]. Specifically, growth factors including, but
not limited to, members of the FGF family such as bFGF, FGF7, and
FGF10 [87–90] as well as IGF [91] and EGF [92,93], are expressed
and secreted primarily by the stromal compartment of the prostate
and act on their cognate receptors expressed in the luminal or basal
epithelial cells. We did not observe any affect of bFGF, IGF, or
EGF on the proliferation of androgen-insensitive PCC in the presence
or absence of serum in vitro. However, we found that bFGF, but not
other growth factors, enhanced activin A–induced serum-dependent
cell proliferation in androgen-insensitive PCCs (Figure 5). Basic fibro-
blast growth factor as well as FGF1, FGF6, FGF8, and FGF9 are all
expressed at increased levels in the prostate tumor epithelium [50–
52,94–96], and bFGF has been associated with metastatic progres-
sion of prostate cancer [96]. Although we observe no effect of bFGF
alone on PC-3 cell proliferation in 1% serum, the synergy observed
between activin A and bFGF on cell proliferation is consistent with
previous in vivo findings that bFGF promotes metastasis in mouse
models [96]. The synergistic effect of bFGF and activin A on PCC
proliferation is important in the context that both bFGF and ac-
tivin A are actively synthesized by PEC and that activin A secretion
occurs in more aggressive cell phenotypes [27,28], supporting an auto-
crine function in the growth of advanced prostate cancers. Thus,
whether activin A–induced PCC proliferation is normal or abnormal
Figure 5. Basic fibroblast growth factor synergizes with activin A to
induce serum-dependent PCC proliferation. PC-3 cells were plated
at 40% confluence in medium ± 1% serum for 24 hours before
being treated with EGF, IGF-1, and bFGF (10 or 25 ng/ml) ± activin
(2.5 ng/ml). Cell proliferation was assessed using the MTS assay
after 3 days. Results are presented as a mean percentage of un-
treated control ± SEM; n= 4 (#significantly different from 1% serum
control without activin A, P < .01; *significantly different from 1%
serum control without activin A, P < .01; @significantly different
from 1% serum control with activin A, P < .001).
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may depend on the microenvironmental expression levels of bFGF
and vice versa.
ActRII Signaling Modulates ADAM-15 Expression in PCCs
and Neuroblastoma Cells
Suppression of ActRII signaling did not induce PCC apoptosis
(Figure 2F ), indicating that ActRII-mediated attachment mediates
cell fate. In this respect, we have shown for the first time that ActRII
signaling regulates ADAM-15 expression, a disintegrin whose expres-
sion has been highly correlated with the metastatic potential of PECs
[46]. Suppression of ActRII signaling increased ADAM-15 expres-
sion and promoted cell detachment in PCCs and neuroblastoma
cells (Figures 2 and 3), two factors associated with metastasis of pri-
mary tumors [46–49]. Thus ActRII seems to mediate cell attachment
via ADAM-15, which has been shown by Najy et al. [97] to support
prostate cancer metastasis by modulating tumor cell–endothelial cell
interaction. Interestingly, substantial decreases in P-Smad2 and Smad4
levels are found in tumor specimens with primary Gleason grades 3
and 4, whereas in grade 5, levels are markedly higher [98]. Because
the cellular phenotype of Gleason grades 3 and 4 is indicative of
cellular invasion into the surrounding stroma, these results strongly
support our findings that activin A regulates ECM adhesion and in-
dicate that PCC may be migrating toward tissue environments of
higher activin A secretion. Thus, the metastatic potential of PCCs
may depend on ActRII signaling; a decrease in activin A (or high in-
hibin expression) would promote cell detachment from its ECM, with
relocalization to a new tissue; reattachment would be dependent on a
high microenvironmental level of activin A (or low inhibin) expression.
Put another way, the microenvironmental expression of activins may
dictate where PCCs take residence and explain why certain tumors
preferentially metastasize to particular tissues.
Conclusions
Given the finding that activin A is pro-proliferative and, based
on our novel finding, that ActRII signaling regulates the expression
of the disintegrin ADAM-15, we propose a model for aggressive
cancer progression, i.e., when there is sufficient ActRII signaling,
ADAM-15 expression decreases and PCCs will be adhered to the
ECM and can proliferate. When ActRII signaling is insufficient,
ADAM-15 expression dramatically increases, leading to detachment
of cells from the ECM. Cell detachment can lead to either apoptotic
cell death or metastasis should the cell find an environment contain-
ing adequate activin A and bFGF. Thus, our findings have important
implications for the determination of cell fate.
That neither activin A nor bFGF alone was sufficient for PCC
proliferation indicates that additional serum factors are required to
induce cell proliferation. Alterations in serum hormone composition
with the dysregulation of the HPG axis during aging and in disease
states will have a marked effect on both the proliferative and meta-
static potential of PCC. For example, inhibin levels decline markedly
with reproductive senescence during aging leading to unopposed
activin signaling due to a high serum ratio of activin to inhibin. That
the activin/inhibin ratio is important is indicated by the fact that in-
hibin α is not detectable in malignant prostatic cells or prostate can-
cer cell lines [66,67]. Further identification of the exact endocrine
and autocrine/paracrine factors that synergize with activin A is there-
fore important.
There are currently few options for the treatment of androgen-
insensitive metastatic prostate cancers. Aside from androgen signaling,
our results indicate that blocking ActRII signaling may be a thera-
peutic strategy for age-related cancers. However, given the metastatic
potential associated with decreased ActRII signaling, therapeutic strate-
gies will need to consider suppressing ActRII signaling along with
antimetastatic or tumor-specific proapoptotic agents. Conversely, ther-
apeutic strategies that upregulate ActRII signaling to suppress metasta-
sis may inadvertently promote tumor growth. Because ActRII signaling
also was necessary for neuroblastoma cell proliferation and cell adhe-
sion, these therapeutic strategies also may apply to other cancer types.
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Figure W1. Suppression of ActRII signaling induces morphological changes in PCC. Antisense and sense oligonucleotides were designed
against ActRIIA or ActRIIB from positions near the cDNA start codon and synthesized by integrated DNA Technologies (Coralville, IA; see
Table 1). Each oligonucleotide was dissolved in sterile doubly deionized H2O to a final concentration of 100 μM. Double-stranded (ds)
antisense was prepared by incubating the sense and the antisense oligonucleotides at 94°C before cooling to room temperature. PC-3
cells were cultured in F12 medium with 5% serum for 1 day before treatment ± ActRIIA or ActRIIB ds antisense or sense oligonucleotides
for 3 days. Magnification is given on the figure. Scale, 50 μm.
